New York University

Leiden University Medical Center

Argenx Iip Bv

Steven J Burden

Karen Silence

Christophe Blanchetot

Akiko Koide

Shohei Koide

Nadia Leloup

Julien Oury

Roeland Vanhauwaert

Maartje Huijbers

Wei Zhang

Johannes J Verschuuren

Silvère M Van Der Maarel

The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.

Therapeutic musk antibodies

Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.

Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays to identify modulators of MuSK activity. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to alleviate or delay motor dysfunction in subjects afflicted with a disorder associated with nerve terminal loss or fragmentation, such as amyotrophic lateral sclerosis, sarcopenia, or anti-MuSK myasthenia gravis.

Method of treating motor neuron disease with an antibody that agonizes MuSK

Growing community of inventors

New York, NY, United States of America

Steven J Burden